| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenue | 1,256 | 1,504 | 1,211 | 1,163 |
| Cost of revenue | 1,625 | 1,859 | 1,697 | 1,563 |
| Sales and marketing | 5,002 | 5,343 | 4,291 | 4,007 |
| General and administrative | 5,432 | 6,483 | 5,605 | 5,617 |
| Amortization of acquired intangible assets | 105 | 106 | 105 | 105 |
| Research and development | 1,206 | 1,723 | 1,272 | 1,255 |
| Total operating expenses | 13,370 | 15,514 | 12,970 | 12,547 |
| Operating loss | -12,114 | -14,010 | -11,759 | -11,384 |
| Interest income | 70 | 109 | 101 | 110 |
| Interest expense | 6 | 5 | 2 | 6 |
| Change in fair value - senior secured convertible note | -1,859 | -1,914* | NaN | NaN |
| Debt extinguishments loss - senior secured convertible note | NaN | 0* | NaN | 0 |
| Change in fair value - senior secured convertible note | NaN | NaN | -2,341 | -6,841 |
| Equity issuance cost extinguishment | NaN | -446* | 1,078 | NaN |
| Other income (expense), net | -1,795 | -2,256 | 1,362 | 6,945 |
| Loss before provision for income tax | -13,909 | -16,266 | -10,397 | -4,439 |
| Provision for income taxes | 0 | 0 | NaN | 0 |
| Net loss attributable to lucid diagnostics inc | -13,909 | -16,266 | -10,397 | -4,439 |
| Dividends-Series AAnd A1Preferred Stock | NaN | 0* | NaN | NaN |
| Less series b and series b-1 convertible preferred stock dividends earned | NaN | NaN | NaN | 3,449 |
| Dividends-Series BAnd B1Preferred Stock | NaN | 0* | NaN | NaN |
| Less series b convertible preferred stock dividends earned | 9,719 | NaN | NaN | 0 |
| Net loss attributable to lucid diagnostics inc. common stockholders | -23,628 | -16,266 | -10,397 | -7,888 |
| Basic EPS | -0.17 | -0.16 | -0.1 | -0.08 |
| Diluted EPS | NaN | NaN | -0.1 | -0.08 |
| Basic Average Shares | 140,096,782 | 101,946,871* | 108,176,088 | 98,989,161 |
| Diluted Average Shares | NaN | NaN | 108,176,088 | 98,989,161 |
Lucid Diagnostics Inc. (LUCD)
Lucid Diagnostics Inc. (LUCD)